ARTICLE | Clinical News

Neurocrine jumps on Phase III endometriosis data

January 9, 2015 3:05 AM UTC

Neurocrine Biosciences Inc. (NASDAQ:NBIX) jumped $5.60 (26%) to $27.48 on Thursday after partner AbbVie Inc. (NYSE:ABBV) said elagolix ( ABT-620) met its co-primary endpoints in the Phase III M12-665 trial to treat endometriosis.

The top-line data showed 150 mg of elagolix given once daily and 200 mg twice daily reduced scores of non-menstrual pelvic pain and dysmenorrhea associated with endometriosis after three and six months of treatment as measured by the Daily Assessment of Endometriosis Pain scale (p<0.001) compared to placebo. Detailed results will be presented at a medical conference. ...